Literature DB >> 10837102

Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine.

P T Trzepacz1.   

Abstract

This article reviews the literature relevant to improving our understanding of the neural underpinnings of delirium. That the characteristic symptoms of delirium occur as a result of a wide diversity of causes supports the concept of a ""final common pathway. " What constitutes this may involve certain brain regions or circuits and certain neurotransmitters. Neuroanatomical data derived from neuroimaging and lesion reports suggest the importance of pathways in prefrontal cortex, thalamus, fusiform cortex, posterior parietal cortex, and basal ganglia. Neurotransmitters most implicated in delirium that could be candidates to mediate the characteristic symptoms of delirium, as well as the electroencephalogram changes, are acetylcholine and dopamine. Acetylcholine deficiency and dopamine excess---absolute and/or relative to each other---appear to be critical in the final common pathway. These neurotransmitters affect each other, depending on the receptor subtype, and their receptor distribution among layers of cortex in areas such as prefrontal cortex and temporal lobe suggests that cholinergic and dopaminergic neurons could interact with each other during delirium. Electroconvulsive therapy is described as a special situation in which excess dopamine and delirium may have a therapeutic effect on depression recovery, in contrast with the usual association of delirium with negative effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837102     DOI: 10.153/SCNP00500132

Source DB:  PubMed          Journal:  Semin Clin Neuropsychiatry        ISSN: 1084-3612


  84 in total

1.  Optimising management of delirium. Placebo controlled trials of pharmacological treatments are needed.

Authors:  C J Ryan
Journal:  BMJ       Date:  2001-06-30

Review 2.  Pharmacological and nonpharmacological management of delirium in critically ill patients.

Authors:  Dustin M Hipp; E Wesley Ely
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  The neuropsychological course of acute delirium in adult hematopoietic stem cell transplantation patients.

Authors:  Leigh J Beglinger; James A Mills; Stacie M Vik; Kevin Duff; Natalie L Denburg; Michelle T Weckmann; Jane S Paulsen; Roger Gingrich
Journal:  Arch Clin Neuropsychol       Date:  2010-12-23       Impact factor: 2.813

Review 4.  Delirium: where do we stand?

Authors:  Chi-Un Pae; David M Marks; Changsu Han; Ashwin A Patkar; Prakash Masand
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

5.  Olanzapine vs haloperidol: treating delirium in a critical care setting.

Authors:  Yoanna K Skrobik; Nicolas Bergeron; Marc Dumont; Stewart B Gottfried
Journal:  Intensive Care Med       Date:  2003-12-19       Impact factor: 17.440

Review 6.  Obstructive sleep apnea and delirium: exploring possible mechanisms.

Authors:  Aibek E Mirrakhimov; Carey L Brewbaker; Andrew D Krystal; Madan M Kwatra
Journal:  Sleep Breath       Date:  2013-04-14       Impact factor: 2.816

7.  Delirium after cardiac surgery: have we overlooked obstructive sleep apnea?

Authors:  Aibek E Mirrakhimov; Timothy Yen; Madan M Kwatra
Journal:  Med Hypotheses       Date:  2013-04-22       Impact factor: 1.538

8.  Delirium: underrecognized and undertreated.

Authors:  Chi-Un Pae; David M Marks; Changsu Han; Ashwin A Patkar; Prakash Masand
Journal:  Curr Treat Options Neurol       Date:  2008-09       Impact factor: 3.598

9.  Post-operative delirium after hip fracture treatment - a review of the current literature.

Authors:  Theocharis Chr Kyziridis
Journal:  Psychosoc Med       Date:  2006-02-08

Review 10.  Bench-to-bedside review: delirium in ICU patients - importance of sleep deprivation.

Authors:  Gerald L Weinhouse; Richard J Schwab; Paula L Watson; Namrata Patil; Bernardino Vaccaro; Pratik Pandharipande; E Wesley Ely
Journal:  Crit Care       Date:  2009-12-07       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.